Business Wire

CGTN: China Vows to Expand All-Around Opening-Up at Shenzhen SEZ's 40th Anniversary

14.10.2020 17:45:00 EEST | Business Wire | Press release

Share

China on Wednesday vowed to unswervingly expand the all-around opening-up of its economy as it held a grand gathering marking the 40th anniversary of the establishment of the Shenzhen Special Economic Zone (SEZ) in this boomtown in southern Guangdong Province.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201014005662/en/

On August 26, 1980, China's national legislature approved the establishment of special economic zones in Shenzhen, Zhuhai and Shantou in Guangdong Province and Xiamen in Fujian Province. Over the past four decades, Shenzhen has been transformed from a small fishing village into a modern metropolis with a permanent population of over 13 million.

Read the article here.

"The world economy is currently facing complicated challenges. By no means should we be stopped by the reversing trends and tides. We should choose the right side of the history to unswervingly expand opening-up in an all-round way, and promote the building of an open world economy and the building of a community with a shared future for mankind," Chinese President Xi Jinping told the gathering.

At a time when the global economic recovery has been complicated by the COVID-19 pandemic and anti-globalization sentiment, China in May this year brought to the table a new development pattern. Known as "dual circulation," it takes the domestic market as the mainstay while letting domestic and foreign markets boost each other.

"The new development pattern is not a closed domestic circulation, but an open domestic and international dual circulation," Xi, also general secretary of the Communist Party of China Central Committee and chairman of the Central Military Commission, stressed in the speech.

He pointed out the need to explore a more flexible policy system and a more scientific management system in domestic and international trade, investment and financing, fiscal and tax affairs, financial innovation and border entry and exit.

Shenzhen, a miracle in world development

Shenzhen is a brand-new city created by the CPC and the Chinese people since the country's reform and opening-up and its development over the past 40 years is a miracle in the world development history, Xi said.

From 1980 to 2019, Shenzhen's GDP rose from 270 million yuan to 2.7 trillion yuan ($40 million to $400 billion), with an average annual growth rate of 20.7 percent, according to Xi.

Its fiscal revenue also increased from less than 100 million yuan to 942.4 billion yuan ($14.9 million to $139.8 billion) during the period.

Its total imports and exports climbed from $18 million in 1980 to $431.5 billion in 2019, an average annual growth rate of 26.1 percent, contributing to an all-around opening up, Xi summarized.

People's livelihoods have also greatly improved in Shenzhen, with tremendous advancements in education, medical care, housing and other areas. Its per capita disposable income skyrocketed to 62,500 yuan ($9,272) in 2019, a 31.6-fold growth compared to that of 1985.

Valuable experience

Xi stressed the valuable experience from the development miracles of the special economic zones (SEZs) including Shenzhen.

Below is some of the advice offered by the president:

-- adhere to the concept that development is of paramount importance, insist on the practices of daring to try and daring to be the first, and pursue reform breakthroughs through creative thoughts.

-- remain committed to opening-up on all fronts and continuously enhance the attractiveness of "bringing in" and the competitiveness of "going out."

-- take innovation as the primary driving force and win the upper hand in global technological revolution and industrial transformation.

-- follow the people-centered philosophy of development to allow the people to benefit more from the achievements of reform and development in a fairer way.

-- ensure scientific legislation, strict law enforcement, judicial impartiality and universal law-abiding to make rule of law an important guarantee for the development of the SEZs.

-- carry out the philosophy of "lucid waters and lush mountains are invaluable assets" to achieve sustained development of economy and society as well as ecology and environment in a comprehensive and coordinated way.

-- implement the fundamental principle of "One Country, Two Systems" in a comprehensive and accurate way, and promote the integrated development of the mainland and Hong Kong and Macao.

-- give full play to the leading and exemplary role of the SEZs while making overall plans for the country, so that they can contribute more to national development.

'Engine' for Guangdong-Hong Kong-Macao Greater Bay Area

Hailing Shenzhen as an "engine" for the Guangdong-Hong Kong-Macao Greater Bay Area (GBA)'s development, Xi asked Shenzhen to take active moves to further promote the construction of the area and called for efforts to synergize economic rules and mechanisms in the three regions.

The GBA Initiative was first mentioned in China's 13th Five-Year Plan (2016-2020) and aims to combine the three regions in order to turn it into one of the world's top bay areas and world-class city clusters.

The area encompasses the special administrative regions (SAR) of Hong Kong and Macao, as well as cities of Guangzhou, Shenzhen, Zhuhai, Dongguan, Huizhou, Zhongshan, Foshan, Zhaoqing and Jiangmen in southern China's Guangdong Province.

Local governments need to build regional railroads, allowing talents and goods to flow between the area more efficiently, which will improve market integration, said Xi.

The country will deepen the reform and opening-up of the Qianhai-Shenzhen-Hong Kong pilot cooperation zone and speed up the construction of a comprehensive national science center in the GBA to enhance coordination and cooperation with Hong Kong and Macao.

The GBA's platform should be fully utilized to attract more young talents from Hong Kong and Macao to come to the region to study, work and build a life, providing them with a deeper and wider level of communication and understanding of each other, the president continued.

Xi welcomed greater participation of foreign countries in the reform, opening-up and development of China's special economic zones.

He said foreign participation has been indispensable in building the economic zones over the past 40 years, assisting in the creation of vast development opportunities and offering development benefits for foreign countries.

Shenzhen, the best example for the need of further opening-up: experts

Continuous reform and wider opening-up were key terms in President Xi's speech at the grand gathering, or as some experts pointed out, the southern Chinese city is the best example that shows the need for further opening-up.

"As China's first special economic zone and through the launch of a market-driven scheme that supported the attraction of a large number of foreign investments, the city has become instrumental in making China a prominent player in today's global economy," commented Matteo Giovannini, a Beijing-based finance professional.

The city is home to various leading Chinese tech companies, including telecoms giant Huawei and technology conglomerate Tencent, two of the major companies that the U.S. has been putting pressure on in the most recently souring China-U.S. ties. Some say President Xi's trip "soothes their nerves."

"Xi's visit to Shenzhen and the unveiling of the plan are aimed to encourage the development of the tech industry," Chief Economist for Hang Seng Bank Dan Wang told South China Morning Post.

According to Giovannini, the trip also shines a light at China's continuous determination to open its arms to the international community.

"(His trip) represents an opportunity to emphasize China's uninterrupted commitment to further domestic integration and market opening-up to the rest of the world," he said.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye